These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

673 related items for PubMed ID: 27716172

  • 1. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
    Papp KA, Bissonnette R, Gooderham M, Feldman SR, Iversen L, Soung J, Draelos Z, Mamolo C, Purohit V, Wang C, Ports WC.
    BMC Dermatol; 2016 Oct 03; 16(1):15. PubMed ID: 27716172
    [Abstract] [Full Text] [Related]

  • 2. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
    Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, Papp K.
    Br J Dermatol; 2013 Jul 03; 169(1):137-45. PubMed ID: 23387374
    [Abstract] [Full Text] [Related]

  • 3. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
    Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S.
    J Am Acad Dermatol; 2016 May 03; 74(5):841-50. PubMed ID: 26899199
    [Abstract] [Full Text] [Related]

  • 4. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
    Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R, OPT Pivotal 1 and OPT Pivotal 2 investigators.
    Br J Dermatol; 2015 Oct 03; 173(4):949-61. PubMed ID: 26149717
    [Abstract] [Full Text] [Related]

  • 5. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
    Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, Wang C, Purohit V, Mamolo C, Papacharalambous J, Ports WC.
    Br J Dermatol; 2016 Nov 03; 175(5):902-911. PubMed ID: 27423107
    [Abstract] [Full Text] [Related]

  • 6. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R, OPT Compare Investigators.
    Lancet; 2015 Aug 08; 386(9993):552-61. PubMed ID: 26051365
    [Abstract] [Full Text] [Related]

  • 7. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
    Bissonnette R, Iversen L, Sofen H, Griffiths CE, Foley P, Romiti R, Bachinsky M, Rottinghaus ST, Tan H, Proulx J, Valdez H, Gupta P, Mallbris L, Wolk R.
    Br J Dermatol; 2015 Aug 08; 172(5):1395-406. PubMed ID: 25418186
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
    Menter A, Papp KA, Tan H, Tyring S, Wolk R, Buonanno M.
    J Drugs Dermatol; 2014 Mar 08; 13(3):252-6. PubMed ID: 24595567
    [Abstract] [Full Text] [Related]

  • 9. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
    Asahina A, Etoh T, Igarashi A, Imafuku S, Saeki H, Shibasaki Y, Tomochika Y, Toyoizumi S, Nagaoka M, Ohtsuki M, study investigators.
    J Dermatol; 2016 Aug 08; 43(8):869-80. PubMed ID: 26875540
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
    Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness JA.
    Br J Dermatol; 2012 Sep 08; 167(3):668-77. PubMed ID: 22924949
    [Abstract] [Full Text] [Related]

  • 11. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.
    Zhang J, Tsai TF, Lee MG, Zheng M, Wang G, Jin H, Gu J, Li R, Liu Q, Chen J, Tu C, Qi C, Zhu H, Ports WC, Crook T.
    J Dermatol Sci; 2017 Oct 08; 88(1):36-45. PubMed ID: 28558978
    [Abstract] [Full Text] [Related]

  • 12. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
    Abe M, Nishigori C, Torii H, Ihn H, Ito K, Nagaoka M, Isogawa N, Kawaguchi I, Tomochika Y, Kobayashi M, Tallman AM, Papp KA.
    J Dermatol; 2017 Nov 08; 44(11):1228-1237. PubMed ID: 28714180
    [Abstract] [Full Text] [Related]

  • 13. Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.
    Griffiths CE, Vender R, Sofen H, Kircik L, Tan H, Rottinghaus ST, Bachinsky M, Mallbris L, Mamolo C.
    J Eur Acad Dermatol Venereol; 2017 Feb 08; 31(2):323-332. PubMed ID: 27600367
    [Abstract] [Full Text] [Related]

  • 14. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.
    Valenzuela F, Korman NJ, Bissonnette R, Bakos N, Tsai TF, Harper MK, Ports WC, Tan H, Tallman A, Valdez H, Gardner AC.
    Br J Dermatol; 2018 Oct 08; 179(4):853-862. PubMed ID: 29782642
    [Abstract] [Full Text] [Related]

  • 15. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
    Mamolo C, Harness J, Tan H, Menter A.
    J Eur Acad Dermatol Venereol; 2014 Feb 08; 28(2):192-203. PubMed ID: 23294276
    [Abstract] [Full Text] [Related]

  • 16. Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
    Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R.
    Br J Dermatol; 2019 Jan 08; 180(1):67-75. PubMed ID: 30188571
    [Abstract] [Full Text] [Related]

  • 17. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
    Zhang L, Guo L, Wang L, Jiang X.
    J Eur Acad Dermatol Venereol; 2022 Nov 08; 36(11):1937-1946. PubMed ID: 35608188
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.
    Menter MA, Papp KA, Cather J, Leonardi C, Pariser DM, Krueger JG, Wohlrab J, Amaya-Guerra M, Kaszuba A, Nadashkevich O, Tsai TF, Gupta P, Tan H, Valdez H, Mallbris L, Tatulych S.
    J Drugs Dermatol; 2016 May 01; 15(5):568-80. PubMed ID: 27168266
    [Abstract] [Full Text] [Related]

  • 19. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF, Gower RG, Xu J, Alam MS, Su JC, Myers DE, Sanders P, Vlahos B, Zang C, Lan J, Werth J.
    Am J Clin Dermatol; 2023 Jul 01; 24(4):623-635. PubMed ID: 37184828
    [Abstract] [Full Text] [Related]

  • 20. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
    Feldman SR, Thaçi D, Gooderham M, Augustin M, de la Cruz C, Mallbris L, Buonanno M, Tatulych S, Kaur M, Lan S, Valdez H, Mamolo C.
    J Am Acad Dermatol; 2016 Dec 01; 75(6):1162-1170.e3. PubMed ID: 27692733
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.